Company intelligence / Profile preview

Biodol

Clapiers (HQ), Occitanie, Francebiodol.eu ↗

Ownership: Private
Development stage: Preclinical

Overview

Biodol Therapeutics is developing first-in-class compounds for pain management, focusing on FLT3 receptor inhibition. Their compounds can be used as oral monotherapy for neuropathic pain and in combination with opioids to enhance analgesia while reducing opioid tolerance and hyperalgesia.

Therapeutic areas: Neurology
Modalities: Small moleculesNegative Allosteric Modulators (NAMs)
Industry: Biotech

Drug pipeline

1 asset

BDT272

Pre-clinical

Indications: Chronic pain, Neuropathic pain

Partnerships

V-Bio VenturesBPI FranceInstitute for Neurosciences of MontpellierLaboratory for Therapeutic Innovation in Strasbourg

Beyond the preview

Go deeper on Biodol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biodol.

Explore the full profile